Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$2.70

0.05 (1.89%)

, ADAP

Adaptimmune

$4.22

0.06 (1.44%)

04:55
01/12/17
01/12
04:55
01/12/17
04:55

Trout Group to hold a conference

Trout Group Annual 1:1 Management Access Event to be held in San Francisco on January 9-12.

ACRX

AcelRx

$2.70

0.05 (1.89%)

ADAP

Adaptimmune

$4.22

0.06 (1.44%)

AMRN

Amarin

$2.99

-0.04 (-1.32%)

ARNA

Arena Pharmaceuticals

$1.41

-0.03 (-2.08%)

CASC

Cascadian Therapeutics

$4.64

-0.13 (-2.73%)

DBVT

DBV Technologies

$34.96

-0.29 (-0.82%)

ENZ

Enzo Biochem

GWPH

GW Pharmaceuticals

$119.06

-4.75 (-3.84%)

GERN

Geron

$2.10

-0.1 (-4.55%)

XLRN

Acceleron

$25.70

-1.01 (-3.78%)

MIRN

Mirna Therapeutics

$1.97

-0.0393 (-1.96%)

RDHL

RedHill Biopharma

$10.55

0.1 (0.96%)

RPRX

Repros Therapeutics

$1.39

-0.01 (-0.71%)

RIGL

Rigel Pharmaceuticals

$2.35

-0.08 (-3.29%)

VVUS

VIVUS

$1.21

-0.03 (-2.42%)

CUR

Neuralstem

$4.65

-1.41 (-23.27%)

NVLS

Changed to ALPN

$2.27

-0.04 (-1.73%)

OMED

OncoMed

$8.15

-0.6 (-6.86%)

PIRS

Pieris Pharmaceuticals

$1.87

0.05 (2.75%)

RETA

Reata Pharmaceuticals

$22.60

-0.8 (-3.42%)

RARE

Ultragenyx

$71.10

-2.75 (-3.72%)

STML

Stemline

$13.45

-0.5 (-3.58%)

  • 12

    Jan

  • 01

    Feb

ACRX AcelRx
$2.70

0.05 (1.89%)

10/04/16
JEFF
10/04/16
NO CHANGE
Target $7
JEFF
Buy
Jefferies says physician survey bodes well for AcelRx
Jefferies analyst Hugo Ong says his firm's first Emergency Department physician survey on trends for acute pain management suggests a positive outlook for AcelRx's ARX-04. Physicians expect to use the drug, which could be available by the end of 2017, in 19% of their patients with moderate pain and 27% with severe pain in 2018, Ong tells investors in a research note. He believes the survey bodes well for ARX-04 and reiterates a Buy rating on AcelRx with a $7 price target.
04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/14/16
JANY
04/14/16
INITIATION
Target $11
JANY
Neutral
AcelRx initiated with a Neutral at Janney Capital
Target $11.
09/15/16
ROTH
09/15/16
NO CHANGE
Target $15
ROTH
Buy
AcelRx price target raised to $15 from $11 at Roth Capital
ADAP Adaptimmune
$4.22

0.06 (1.44%)

10/24/16
BOFA
10/24/16
DOWNGRADE
BOFA
Underperform
Adaptimmune downgraded to Underperform from Neutral at BofA/Merrill
11/10/16
LEER
11/10/16
NO CHANGE
LEER
Outperform
Removal of partial clinical hold removes overhang on Adaptimmune, says Leerink
Leerink analyst Michael Schmidt notes that Adaptimmune announced that the FDA has removed the partial clinical hold on the planned study NY-ESO TCR T cell therapy in Myxoid/Round Cell Liposarcoma, which was due to requests of additional information on chemistry and manufacturing controls and the clinical trial protocol prior to study initiation. The analyst believes that the removal of the partial clinical hold should remove an overhang on Adaptimmune's shares, and says management anticipates study initiation in Q4. He reiterates an Outperform rating on the shares.
10/13/16
SBSH
10/13/16
NO CHANGE
Target $15
SBSH
Buy
Adaptimmune selloff yesterday unwarranted, says Citi
Citi analyst Robyn Karnauskas says yesterday's ovarian cancer non-response data from Adaptimmune Therapeutics are not new. Investors are concerned as the press release noted that no objective clinical responses were seen among initial ovarian cancer patients treated with ADAP TCR treatment, but information was disclosed at ASCO in June, Karnauskas writes in a research note. The analyst keeps a Buy rating on Adaptimmune with a $15 price target.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.
AMRN Amarin
$2.99

-0.04 (-1.32%)

10/19/16
SBSH
10/19/16
INITIATION
Target $5
SBSH
Buy
Citi starts Amarin with Buy rating, $5 price target
Citi analyst Joel Beatty initiated Amarin with a Buy rating and $5 price target. The biopharmaceutical company closed yesterday up 1c to $3.00. If the ongoing REDUCE-IT outcomes trial for the company's sole drug Vascepa is positive in late 2017 or early 2018, the label will be expanded to treat adults with triglycerides greater than or equal to 150, which is almost a 20 times larger market than the drug's current indication, Beatty tells investors in a research note. The analyst estimates the stock would trade up to $16 per share on news of a positive trial. In this scenario, he models Vascepa sales peaking at $2.6B in 2024.
05/12/16
05/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amarin (AMRN) assumed with a Buy at Jefferies by analyst Hugo Ong, who said off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit. 2. Theravance Biopharma (TBPH) initiated with an Outperform at Leerink with analyst Paul Matteis saying he sees a favorable risk/reward ahead of a string of clinical/commercial catalysts over the next year. 3. Graphic Packaging (GPK) initiated with a Conviction Buy at Goldman. 4. Owens-Illinois (OI) initiated with a Sell at Goldman. 5. Sonoco Products (SON) initiated with a Neutral at Goldman. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
CANT
10/04/16
INITIATION
Target $6
CANT
Buy
Amarin initiated with a Buy at Cantor
Cantor initiated Amarin with a Buy and a $6 price target.
10/19/16
10/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DuPont (DD) initiated with a Buy at Nomura. 2. Square (SQ) initiated with a Neutral at Credit Suisse. 3. GoDaddy (GDDY) initiated with a Buy at Cantor. 4. Wix.com (WIX) was initiated with a Buy at Cantor while the firm initiated Web.com (WEB) initiated with a Hold. 5. Amarin (AMRN) initiated with a Buy at Citi. The firm has a $5 price target on the stock. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ARNA Arena Pharmaceuticals
$1.41

-0.03 (-2.08%)

03/01/16
PIPR
03/01/16
NO CHANGE
Target $3.5
PIPR
Overweight
Arena Pharmaceuticals price target lowered to $3.50 from $5 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his forecast for Belviq revenue due to Arena in 2016 to $16M from $21.5M after the company reported sales of the weight loss drug were down sequentially in the fourth quarter. The analyst keeps an Overweight rating on Arena shares, noting that data for a Phase II trial of its highest profile pipeline asset, APD334, is now expected in 2017.
09/15/16
09/15/16
INITIATION
Target $6

Outperform
Arena Pharmaceuticals initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Arena Pharmaceuticals with an Outperform rating and $6 price target.
01/05/17
JMPS
01/05/17
NO CHANGE
JMPS
Market Perform
JMP Securities views Arena amended agreement with Eisai 'favorably'
JMP Securities analyst Jason Butler says Arena Pharmaceuticals' (ARNA) amended agreement with Eisai (ESALY) reduces resource and capital constraints on the company while maintaining "attractive" long-term upside from Belviq success. The analyst notes that Eisai will now have full global development and marketing rights to Belviq in exchange for lowering Arena's royalties and cost contributions, which he views "favorably" as the commercial potential for it remains limited. Furthermore, the new agreement allows Arena to further focus its energies and resources in its Phase 2 pipeline assets, Butler adds. He reiterates a Market Perform on Arena Pharmaceuticals' shares.
09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
CASC Cascadian Therapeutics
$4.64

-0.13 (-2.73%)

06/22/16
06/22/16
NO CHANGE

Cascade files to sell common stock, convertible preferred stock
Cascade announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Additionally, concurrently with the common stock offering, Cascadian Therapeutics intends to sell shares of Series D convertible preferred stock having an aggregate value of up to $13.8 million directly to affiliates of BVF Partners L.P., which are existing stockholders and affiliates of a member of the board of directors of Cascadian Therapeutics. Cowen and Company, LLC is acting as the sole book-running manager, and Trout Capital LLC is acting as a co-manager in the offering of common stock. Cowen and Company, LLC and Trout Capital LLC will also act as placement agents in connection with the sale of Series D convertible preferred stock.
DBVT DBV Technologies
$34.96

-0.29 (-0.82%)

10/25/16
JEFF
10/25/16
NO CHANGE
Target $47
JEFF
Buy
DBV Technologies data in-line with expectations, says Jefferies
Jefferies analyst Eun Yang says the year three Phase II data for Viaskin Peanut show durability of response and are in-line with expectations. The Phase III trial has been fully enrolled ahead of schedule, Yang tells investors in a research note. The analyst remains positive on DBV shares with a Buy rating and $47 price target.
01/05/17
JEFF
01/05/17
NO CHANGE
JEFF
Celgene, Alkermes among Jefferies' top 2017 Biotech picks
Jefferies' Biotechnology equity research team laid out their top picks for 2017. Following a volatile two years, the biotech space seeks to achieve "greater equilibrium" in 2017, the analysts write in a research note. They cite increasing competition, slowing volumes, and ramping payer leverage as reasons to remain selective when picking stocks this year and beyond. Among large-caps, Jefferies likes Celgene (CELG) for its "best-in-class growth" and sees limited downside in Gilead (GILD) shares. In the mid-cap space, the firm favors Alkermes (ALKS) given the prospects for Vivitrol and Aristada and a "strong" neurology pipeline as well as Vertex (VRTX). Jefferies' top small-cap picks include Aevi Genomics Medicine, Alder Biopharmaceuticals (ALDR), AMAG Pharmaceuticals (AMAG), DBV Technologies (DBVT), Immunomedics (IMMU), Ignyta (RXDX), Karyopharm (KPTI), RA Pharmaceuticals (RARX), TherapeuticsMD (TXMD) and Xenon Pharmaceuticals (XENE).
06/28/16
PIPR
06/28/16
NO CHANGE
Target $38
PIPR
Overweight
Piper reiterates Overweight on Aimmune after management meetings
After hosting meetings with management, Piper Jaffray analyst Charles Duncan reiterates an Overweight rating on Aimmune Therapeutics (AIMT) with a $38 price target. The stock closed yesterday down 44c to $11.01 and is down over 40% year-to-date. No matter how the Phase II data is dissected, Aimmune's AR101 appears to produce a higher response rate in about 50% less time than DBV Technologies' (DBVT) Viaskin, Duncan tells investors in a research note. He believes investors may be overlooking future potential drivers of competitive advantage for AR101.
09/26/16
JMPS
09/26/16
INITIATION
Target $47
JMPS
Outperform
DBV Technologies initiated with an Outperform at JMP Securities
JMP Securities analyst Liisa Bayko initiated DBV Technologies with an Outperform and a $47 price target. The analyst is confident Viaskin for peanut allergy will show a strong safety and tolerability profile and we will be paying close attention to the level of desensitization in children and projects $2B in sales by 2028..
ENZ Enzo Biochem

10/14/16
CHLM
10/14/16
NO CHANGE
Target $8
CHLM
Buy
Enzo Biochem risk/reward remains attractive, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said Enzo Biochem's Q4 report was essentially in line and reinforces his views that Enzo's clinical lab would be highly attractive to numerous strategic buyers and that the lab alone has a value approaching Enzo's current enterprise value. He views risk/reward as attractive given potential upside from the AmpiProbe platform and additional legal settlements. Bonello rates Enzo a Buy with a $8 price target.
GWPH GW Pharmaceuticals
$119.06

-4.75 (-3.84%)

12/05/16
PIPR
12/05/16
NO CHANGE
Target $147
PIPR
Overweight
GW data support approval and broad use, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says the additional Epidiolex data from the first Dravet and Lennox-Gastaut studies presented over the weekend by GW Pharmaceuticals support approval and broad use. The totality of the data indicate an approvable drug, with secondary analyses supportive of a "meaningful benefit" with a well tolerated profile in a highly refractory patient population, Schimmer tells investors in a research note. He reiterates an Overweight rating on GW shares with a $147 price target.
12/05/16
CANT
12/05/16
NO CHANGE
Target $208
CANT
Buy
GW Pharmaceuticals price target raised after Epidiolex data at Cantor
Cantor analyst Elemer Piros raised his price target for GW Pharmaceuticals to $208 from $182 following its Epidiolex data presented at the American Epilepsy Society meeting. The analyst believes the data illustrates "robustness and remarkable consistency" across two distinct forms of epilepsy, Lennox Gastaut and Dravet syndrome and notes that the company laid to rest the largely overblown concern regarding drug interaction with clobazam. Piros believes GW Pharmaceuticals is in "good shape" for a New Drug Application covering both indications by the end of 1H17, and reiterates a Buy rating on the shares.
12/05/16
CANT
12/05/16
NO CHANGE
Target $208
CANT
Buy
GW Pharmaceuticals price target raised to $208 from $182 at Cantor
12/05/16
LEER
12/05/16
NO CHANGE
LEER
Outperform
GW Pharmaceuticals Dravet Phase 3 data supportive of approval, says Leerink
Leerink analyst Paul Matteis notes that while Phase 3 data from GW Pharmaceuticals' Epidiolex study in Dravet Syndrome presented at the American Epilepsy Society were "slightly less robust" than that generated in Lennox Gastaut Syndrome, he remains confident that the trial is very likely to be supportive of approval in the U.S. and Europe. The analyst continues to recommend the stock given his expectation of approval, a fast launch, and a robust commercial opportunity in an area of very high unmet medical need. Matteis reiterates an Outperform rating on the shares.
GERN Geron
$2.10

-0.1 (-4.55%)

09/13/16
09/13/16
NO CHANGE
Target $5

Outperform
Geron price target lowered to $5 from $6 at FBR Capital
FBR Capital analyst Thomas Yip lowered his price target for Geron to $5 citing higher clinical risk for imetelstat and a six-month delay of his projected approval for the myelofibrosis indication. The analyst views the Phase II IMbark 12-week analysis as inconclusive and says he remains confident in imetelstat. Yip keeps an Outperform rating on Geron.
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Geron initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Geron with a Neutral saying the company is in a period of executing on two large trials in MF and MDS with a relatively thin data flow and expects shares to be range-bound until major data release, potentially in late 2017 or 2018.
XLRN Acceleron
$25.70

-1.01 (-3.78%)

08/19/16
08/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aratana Therapeutics (PETX) assumed with a Buy at Jefferies. 2. Arbutus Biopharma (ABUS) initiated with an Outperform at William Blair. 3. Acceleron (XLRN) initiated with a Buy at BTIG. 4. Agios Pharmaceuticals (AGIO) initiated with a Neutral at BTIG. 5. Suncor (SU) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
SBSH
09/29/16
INITIATION
Target $40
SBSH
Neutral
Acceleron initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Acceleron Pharma with a Neutral rating and $40 price target. The company's pivotal programs are already reflected in the shares while Phase 2 catalysts could provide upside, Karnauskas tells investors in a research note.
12/12/16
OPCO
12/12/16
INITIATION
Target $44
OPCO
Acceleron initiated with an Overweight at Oppenheimer
Oppenheimer analyst Leah Cann initiated Acceleron with an Outperform and a $44 price target saying the successful launch of two experimental products, Luspatercept and Dalantercept, could result in Acceleron having revenues grow to $367.3 million in 2021 from $18.1 million in 2015.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
MIRN Mirna Therapeutics
$1.97

-0.0393 (-1.96%)

09/23/16
HCWC
09/23/16
DOWNGRADE
Target $2
HCWC
Neutral
Mirna Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak downgraded Mirna Therapeutics to Neutral with a $2 price target following the voluntary stop of the MRX34 trial. Mirna may still develop a compelling microRNA-based oncology drug, but there is uncertainty about the delivery technology it may use and the miRNA target it may pursue, Deepak tells investors in a research note.
09/21/16
CANT
09/21/16
DOWNGRADE
Target $2
CANT
Hold
Mirna Therapeutics downgraded to Hold from Buy at Cantor
Cantor Fitzgerald analyst Mara Goldstein downgraded Mirna Therapeutics to Hold and cut her price target for the shares to $2 from $14 citing the stopping of the Phase I trial of MX34. The shares are likely to trade below cash, Goldstein tells investors in a research note. She sees no reason to be more constructive on the shares without a more advanced pipeline.
09/21/16
OPCO
09/21/16
DOWNGRADE
OPCO
Perform
Mirna Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Michelle Gilson downgraded Mirna Therapeutics to Perform following yesterday's announcement that the company is closing its Phase 1 study of lead asset MRX34 due to immune-mediated SAE's observed.
09/12/16
HCWC
09/12/16
INITIATION
Target $6
HCWC
Buy
Mirna Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started Mirna Therapeutics with a Buy rating and $6 price target. The company's "promising" microRNA technology could be a "gift" to long-term investors, Deepak tells investors in a research note.
RDHL RedHill Biopharma
$10.55

0.1 (0.96%)

04/05/16
ROTH
04/05/16
NO CHANGE
Target $26
ROTH
Buy
'Positive momentum' building for RedHill Biopharma, says Roth Capital
Roth Capital analyst Scott Henry sees a continued 'positive momentum' at RedHill Biopharma, with progress toward a Rizaport partnership in Spain and promising proof-of-concept data for RHB-104 to treat multiple sclerosis. Although Henry does not view these as core assets, he believes that this progress validates the company's business model. The analyst reiterates a Buy rating and his $26 price target on the stock.
RPRX Repros Therapeutics
$1.39

-0.01 (-0.71%)

11/16/16
LTCO
11/16/16
UPGRADE
Target $5.5
LTCO
Buy
Repros Therapeutics upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Matt Kaplan upgraded Repros Therapeutics to Buy citing strength of the Proellex Phase 2b uterine fibroid results combined with the positive data also observed in the Proellex endometriosis. The analyst has a $5.50 price target for the shares.
RIGL Rigel Pharmaceuticals
$2.35

-0.08 (-3.29%)

10/20/16
PIPR
10/20/16
NO CHANGE
PIPR
Overweight
Rigel Pharmaceuticals risk/reward remains favorable, says Piper Jaffray
With the stock down nearly 35% in pre-market trading, Piper Jaffray analyst Joshua Schimmer believes the risk/reward on shares of Rigel Pharmaceuticals remains favorable. The company on the conference call did an "excellent job" explaining the failed second Phase III results for fostamatinib in immune thrombocytopenic, Schimmer tells investors in a research note. He believes the drug has a "clear therapeutic benefit" and reiterates an Overweight rating on the stock with an $11 price target.
09/16/16
JEFF
09/16/16
NO CHANGE
Target $9
JEFF
Buy
Jefferies views Rigel restructuring positively, ups target to $9
Jefferies analyst Eun Yang views Rigel Pharmaceuticals' restructuring, which prioritizes fostamatinib commercialization while reducing research workforce, as a positive. The analyst notes the move will have no impact on the company's early programs. She raised her price target for Rigel shares to $9 from $8.50 and keeps a Buy rating on the name. Rigel closed yesterday up 4c to $3.45. The next major catalyst for the stock will be second Phase 3 data for fostamatinib in Immune Thrombocytopenic Purpura in October or November, Yang tells investors in a research note. She expects additional indications opportunities to drive "meaningful share price appreciation."
10/20/16
JPMS
10/20/16
NO CHANGE
JPMS
Overweight
Rigel has 20%-40% near-term downside, says JPMorgan
JPMorgan analyst Anupam Rama believes shares of Rigel Pharmaceuticals now have a regulatory uncertainty overhang after the company's second phase 3 trial of fostamatinib in immune thrombocytopenic missed statistical significance on its primary endpoint.There could ultimately be a registration path forward with combined phase 3 dataset, however, Rama tells investors in a research note. Nonetheless, the analyst sees the potential for 20%-40% share downside in the near-term. Rama has an Overweight rating on Rigel. The stock is down 34% to $2.11 in pre-market trading.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
VVUS VIVUS
$1.21

-0.03 (-2.42%)

02/29/16
RBCM
02/29/16
DOWNGRADE
RBCM
Sector Perform
VIVUS downgraded to Sector Perform from Outperform at RBC Capital
05/04/16
WBTH
05/04/16
DOWNGRADE
WBTH
Hold
VIVUS downgraded to Hold from Buy at WallachBeth
02/29/16
RBCM
02/29/16
DOWNGRADE
RBCM
Sector Perform
VIVUS downgraded on obesity market outlook at RBC Capital
As noted earlier, RBC Capital downgraded VIVUS to Sector Perform from Outperform. The firm says that it expects the company's obesity drug, Qsymia, to have difficulty gaining market share because of the lack of enthusiasm for anti-obesity drugs among doctors and payers in the U.S. Target to $1 from $4.
07/25/16
WBTH
07/25/16
NO CHANGE
Target $2.8
WBTH
Buy
Markman ruling positive for VIVUS, says WallachBeth
WallachBeth analyst Caroline Palomeque views last week's Markman ruling as a positive development for Vivus. The District Court of New Jersey's ruling to adopt the company's claim constructions on its 10 Qsymia patents may bode well for the overall patent infringement case, Palomeque tells investors in a research note. Qsymia has its last patent expiry in 2029, the analyst points out. She keeps a Buy rating on VIVUS with a $2.80 price target.
CUR Neuralstem
$4.65

-1.41 (-23.27%)

10/04/16
BMUR
10/04/16
INITIATION
Target $4
BMUR
Buy
Neuralstem assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Neuralstem with a Buy rating and $4 price target.
08/29/16
ROTH
08/29/16
INITIATION
Target $1.2
ROTH
Buy
Neuralstem initiated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis started Neuralstem with a Buy rating and $1.20 price target.
11/07/16
AGIS
11/07/16
INITIATION
Target $2.25
AGIS
Buy
Neuralstem initiated with a Buy at Aegis
Aegis analyst Jason Wittes initiated Neuralstem with Buy and a $2.25 price target.
08/29/16
08/29/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Axiom by analyst Victor Anthony, who set an $80 price target on shares of the streaming service operator. The company's is seeing rising competition and diminishing pricing power, Anthony tells investors in a research note. He adds that rising content costs will pressure Netflix's ability to meet Street estimates. 2. Invuity (IVTY) initiated with a Buy rating and $25 price target by Craig-Hallum analyst Charles Haff, who believes the company's surgical lighting products offer higher quality resolution and are safer and more effective than the current standard of care in minimally-invasive procedures. 3. Recro Pharma (REPH) initiated by Janney Capital analyst Ken Trbovich with a Buy rating and $21 fair value estimate. 4. Neuralstem (CUR) initiated by Roth Capital analyst Joseph Pantginis with a Buy rating and $1.20 price target. 5. At Home Group (HOME) initiated with an Outperform rating at William Blair and with a Buy rating and $20 price target at Jefferies. To see The Fly's full Street Research coverage, Reference Link
NVLS Changed to ALPN
$2.27

-0.04 (-1.73%)

11/29/16
11/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
11/29/16
DOWNGRADE
Target $3

Neutral
Nivalis Therapeutics downgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney downgraded Nivalis Therapeutics to Neutral from Outperform following the clinical trial failure of its flagship proof-of-concept study of its drug for cystic fibrosis. Skorney lowered his price target to $3 from $29 on Nivalis Therapeutics shares. Nivalis shares have also been downgraded by at least three other firms this morning.
11/29/16
COWN
11/29/16
DOWNGRADE
COWN
Market Perform
Nivalis Therapeutics downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Phil Nadeau downgraded Nivalis Therapeutics to Market Perform from Outperform. The analyst said its proof-of-concept Phase 2 trial for cystic fibrosis demonstrated no benefits for lung function or sweat chloride, two established measures of activity. The drug was the company's primary asset, Nadeau noted.
11/29/16
STFL
11/29/16
DOWNGRADE
STFL
Hold
Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.
OMED OncoMed
$8.15

-0.6 (-6.86%)

09/22/16
HCWC
09/22/16
INITIATION
Target $20
HCWC
Buy
OncoMed initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak started OncoMed Pharmaceuticals (OMED) with a Buy rating and $20 price target. The company is entering a "year of dramatic changes" with upcoming opt-in decisions for its lead drug candidates expected from partners Celgene (CELG), Bayer (BAYRY) and GlaxoSmithKline (GSK), Deepak tells investors in a research note. The analyst believes the partnerships could payoff with long-term benefits.
12/20/16
RHCO
12/20/16
INITIATION
Target $16
RHCO
Buy
OncoMed initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated OncoMed with a Buy and a $16 price target saying positive data from Phase 2 data in pancreatic cancer and Phase 2 data in SCLC expected in 1H 2017, and Phase 1b data with demcizumab + Keytruda in 2H 2017 could drive shares higher. Lawson believes shares are udnervalued and expects near-term data to restore confidence in the stock.
06/06/16
PIPR
06/06/16
NO CHANGE
Target $29
PIPR
Overweight
Piper says confidence in OncoMed increased by ASCO updates
Piper Jaffray analyst Edward Tenthoff noted that OncoMed presented new Phase Ib data from vantictumab and ipafricept at the ASCO meeting, adding that he was "particularly impressed" by early ipafricept signal in ovarian cancer. The analyst, who contends that OncoMed has a "rich pipeline" of seven cancer biotherapeutics in the clinic, keeps an Overweight rating and $29 price target on the stock.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
PIRS Pieris Pharmaceuticals
$1.87

0.05 (2.75%)

08/05/16
ROTH
08/05/16
INITIATION
Target $6
ROTH
Buy
Pieris Pharmaceuticals reinstated with a Buy at Roth Capital
Roth Capital analyst Joseph Pantginis reinstated Pieris Pharmaceuticals with a Buy and $6 price target.
RETA Reata Pharmaceuticals
$22.60

-0.8 (-3.42%)

06/20/16
SBSH
06/20/16
INITIATION
Target $32
SBSH
Buy
Reata Pharmaceuticals initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Reata Pharmaceuticals with a Buy rating and $32 price target. The analyst sees "considerable room" for the company's lead drug, Bardoxolone Methyl, to operate in the pulmonary arterial hypertension market.
06/20/16
COWN
06/20/16
INITIATION
Target $22
COWN
Outperform
Reata Pharmaceuticals initiated with an Outperform at Cowen
Cowen initiated Reata Pharmaceuticals with an Outperform based on the company's potential for clinical and commercial success of its lead candidate bardoxolone in PAH-CTD, which has data in 1H18, as well as significant value in other indications. Cowen has a $22 price target on Reata Pharmaceuticals shares.
RARE Ultragenyx
$71.10

-2.75 (-3.72%)

11/14/16
SBSH
11/14/16
DOWNGRADE
Target $64
SBSH
Sell
Ultragenyx downgraded to Sell from Neutral at Citi
Citi analyst Yigal Nochomovitz downgraded Ultragenyx to Sell after removing Ace-ER sales from his model "in the absence of stronger data." The analyst lowered his price target for the shares to $64 from $66.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.
11/01/16
PIPR
11/01/16
NO CHANGE
Target $82
PIPR
Overweight
Ultragenyx risk/reward favorable after pullback, says Piper Jaffray
Piper Jaffray analyst Steven Breazzano says Ultragenyx's risk/reward profile is favorable following the recent pullback in the shares. The analyst recommends buying the stock based on the blockbuster potential of KRN23 in adult and pediatric X-linked hypophosphatemia patients. After taking a closer look at Ultragenyx's UX007 Phase 2 program for both fatty acid oxidation disorders and Glut1 deficiency syndrome, the analyst sees a greater than 50% chance of success in both. He notes the program would represent "meaningful upside" to his model. He reiterates an Overweight rating on Ultragenyx with an $82 price target.
11/08/16
ADAM
11/08/16
NO CHANGE
Target $108
ADAM
Buy
Ultragenyx price target lowered to $108 from $120 at Canaccord
Canaccord analyst Arlinda Lee lowered her price target on Ultragenyx to $108 from $120 due to an expected increase in R&D spending after the company reported pipeline progress on four clinical candidates and said it expects to file for U.S. KRN23 pediatric approval earlier than expected in the second half of 2017. Lee reiterated her Buy rating on Ultragenyx shares as she expects regulatory approvals in 2017, while also citing its attractive pipeline.
STML Stemline
$13.45

-0.5 (-3.58%)

06/06/16
HCWC
06/06/16
NO CHANGE
Target $38
HCWC
Buy
H.C. Wainwright positive on Stemline after ASCO data
H.C. Wainwright analyst Raghuram Selvaraju reiterates a Buy rating and $38 price target on Stemline Therapeutics following the company's data presentation at the American Society for Clinical Oncology meeting. SL-401 showed robust single agent activity, with an 87% overall response rate across all lines and 100% ORR in first-line subjects, including eight complete responses, Selvaraju tells investors in a research note. The safety profile of SL-401 "appears vastly superior" to that of traditional chemotherapy historically used in treating blastic plasmacytoid dendritic cell neoplasm patients, the analyst contends. He views Stemline as "one of the most compelling value propositions in the oncology sector."

TODAY'S FREE FLY STORIES

STLD

Steel Dynamics

$39.85

0.01 (0.03%)

18:07
12/15/17
12/15
18:07
12/15/17
18:07
Earnings
Steel Dynamics sees Q4 EPS 48c-52c, consensus 55c »

"Despite a lower…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

House plans to vote…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

, SPX

S&P 500

17:42
12/15/17
12/15
17:42
12/15/17
17:42
Periodicals
Republicans release final tax bill proposal, CNBC reports »

Republicans have released…

SPY

SPDR S&P 500 ETF Trust

$266.51

2.21 (0.84%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$162.60

5.4 (3.44%)

17:37
12/15/17
12/15
17:37
12/15/17
17:37
Hot Stocks
McKesson awarded $400M government contract »

McKesson has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$60.94

0.11 (0.18%)

17:34
12/15/17
12/15
17:34
12/15/17
17:34
Syndicate
Breaking Syndicate news story on Ameren »

Ameren files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$57.76

1 (1.76%)

, AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

17:33
12/15/17
12/15
17:33
12/15/17
17:33
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Akamai (AKAM), up…

AKAM

Akamai

$57.76

1 (1.76%)

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

PG

Procter & Gamble

$91.89

0.89 (0.98%)

PETX

Aratana Therapeutics

$5.73

0.15 (2.69%)

HPE

HP Enterprise

$14.41

0.17 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 13

    Dec

GRMN

Garmin

$58.36

-1.1 (-1.85%)

17:32
12/15/17
12/15
17:32
12/15/17
17:32
Recommendations
Garmin analyst commentary at Tigress Financial »

Garmin growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$322.82

5.81 (1.83%)

17:26
12/15/17
12/15
17:26
12/15/17
17:26
Hot Stocks
Lockheed Martin awarded $135.83M government contract »

Lockheed Martin is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

PG

Procter & Gamble

$91.89

0.89 (0.98%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
Peltz to join Procter & Gamble board effective March 1, 2018 »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.89 (0.98%)

, NVS

Novartis

$84.86

0.39 (0.46%)

17:19
12/15/17
12/15
17:19
12/15/17
17:19
Hot Stocks
P&G names Trian's Nelson Peltz, Novartis CEO Jimenez to board »

Procter & Gamble (PG)…

PG

Procter & Gamble

$91.89

0.89 (0.98%)

NVS

Novartis

$84.86

0.39 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 17

    May

SNSS

Sunesis

$3.36

0.16 (5.00%)

17:16
12/15/17
12/15
17:16
12/15/17
17:16
Hot Stocks
Sunesis CEO Swisher to resign, Dayton Misfeldt named interim CEO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, BA

Boeing

$293.94

0.06 (0.02%)

17:09
12/15/17
12/15
17:09
12/15/17
17:09
Hot Stocks
AT&T CEO Stephenson resigns from Boeing board »

According to a regulatory…

T

AT&T

$38.24

0.5 (1.32%)

BA

Boeing

$293.94

0.06 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

HPE

HP Enterprise

$14.41

0.17 (1.19%)

17:03
12/15/17
12/15
17:03
12/15/17
17:03
Syndicate
Breaking Syndicate news story on HP Enterprise »

HP Enterprise files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

FSV

FirstService

$67.87

-0.54 (-0.79%)

17:02
12/15/17
12/15
17:02
12/15/17
17:02
Hot Stocks
Breaking Hot Stocks news story on FirstService »

Jay S. Hennick reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETP

Energy Transfer Partners

$17.50

0.08 (0.46%)

17:01
12/15/17
12/15
17:01
12/15/17
17:01
Hot Stocks
Energy Transfer gets FERC approval to place Rover Pipeline's 1B into service »

Energy Transfer Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

, BTC

Bitcoin

16:56
12/15/17
12/15
16:56
12/15/17
16:56
Periodicals
TD Ameritrade to offer bitcoin futures, CNBC reports »

TD Ameritrade will now…

AMTD

TD Ameritrade

$51.98

1.1 (2.16%)

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$26.90

-0.65 (-2.36%)

16:55
12/15/17
12/15
16:55
12/15/17
16:55
Hot Stocks
Breaking Hot Stocks news story on Health Insurance Innovations »

Cannell Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$24.96

0.13 (0.52%)

16:51
12/15/17
12/15
16:51
12/15/17
16:51
Hot Stocks
Breaking Hot Stocks news story on Regional Management »

Basswood Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBY

NovaBay

$3.35

-0.0668 (-1.96%)

16:50
12/15/17
12/15
16:50
12/15/17
16:50
Syndicate
NovaBay files to sell $12M of common stock »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.24

0.5 (1.32%)

, TWX

Time Warner

$90.25

0.6 (0.67%)

16:50
12/15/17
12/15
16:50
12/15/17
16:50
Periodicals
DOJ, AT&T held unsuccessful settlement talks, Reuters reports »

The U.S. Department of…

T

AT&T

$38.24

0.5 (1.32%)

TWX

Time Warner

$90.25

0.6 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$6.06

0.2 (3.41%)

16:48
12/15/17
12/15
16:48
12/15/17
16:48
Syndicate
Breaking Syndicate news story on Sunrun »

Sunrun files to sell 30M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$6.06

0.2 (3.41%)

16:47
12/15/17
12/15
16:47
12/15/17
16:47
Syndicate
Breaking Syndicate news story on Sunrun »

Sunrun files $328.7M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SINO

Sino-Global

$2.59

0.05 (1.97%)

16:43
12/15/17
12/15
16:43
12/15/17
16:43
Syndicate
Breaking Syndicate news story on Sino-Global »

Sino-Global files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALN

American Lorain

16:35
12/15/17
12/15
16:35
12/15/17
16:35
Hot Stocks
American Lorain regains compliance for continued listing on NYSE »

American Lorain announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$60.02

0.55 (0.92%)

16:32
12/15/17
12/15
16:32
12/15/17
16:32
Hot Stocks
Black Hills Arkansas subsidiary requests rate review for system investments »

Black Hills Corp.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.